SCYNEXIS, Inc. (NASDAQ:SCYX – Get Rating) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.16 and traded as low as $2.54. SCYNEXIS shares last traded at $2.75, with a volume of 176,862 shares.
Analyst Upgrades and Downgrades
Separately, HC Wainwright cut their price target on SCYNEXIS from $14.00 to $8.00 in a report on Friday, May 13th.
SCYNEXIS Stock Performance
The firm has a market cap of $89.59 million, a PE ratio of -1.82 and a beta of 2.06. The company has a debt-to-equity ratio of 1.14, a current ratio of 7.87 and a quick ratio of 7.78. The stock has a 50-day moving average price of $2.04 and a 200 day moving average price of $3.16.
Institutional Investors Weigh In On SCYNEXIS
Institutional investors have recently added to or reduced their stakes in the company. Citigroup Inc. purchased a new stake in shares of SCYNEXIS in the first quarter worth about $26,000. Chicago Partners Investment Group LLC grew its holdings in shares of SCYNEXIS by 20.4% during the first quarter. Chicago Partners Investment Group LLC now owns 50,192 shares of the company’s stock valued at $106,000 after purchasing an additional 8,517 shares during the last quarter. State Street Corp grew its holdings in shares of SCYNEXIS by 9.3% during the first quarter. State Street Corp now owns 78,630 shares of the company’s stock valued at $307,000 after purchasing an additional 6,694 shares during the last quarter. Wealth Effects LLC bought a new position in shares of SCYNEXIS during the fourth quarter valued at approximately $536,000. Finally, DAFNA Capital Management LLC bought a new position in SCYNEXIS in the 4th quarter worth approximately $740,000. Hedge funds and other institutional investors own 55.69% of the company’s stock.
SCYNEXIS Company Profile
SCYNEXIS, Inc, a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).
- Get a free copy of the StockNews.com research report on SCYNEXIS (SCYX)
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- Time To Take A Serious Look At Nikola Stock As Production Starts
- These Are The Top Insider Buying Stocks For July
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.